Literature DB >> 25012994

Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Meghan J Chenoweth1, Maria Novalen1, Larry W Hawk2, Robert A Schnoll3, Tony P George4, Paul M Cinciripini5, Caryn Lerman3, Rachel F Tyndale6.   

Abstract

BACKGROUND: The ratio of 3'hydroxycotinine to cotinine, or nicotine metabolite ratio (NMR), is strongly associated with CYP2A6 genotype, CYP2A6-mediated nicotine and cotinine metabolism, and nicotine clearance. Higher NMR (faster nicotine clearance) is associated retrospectively with heavier smoking and lower cessation rates.
METHODS: NMR as a predictive biomarker of cessation outcomes is being investigated (NCT01314001). In addition to strong CYP2A6 genetic influences on NMR, demographic and hormonal factors alter NMR. Here, we analyzed, for the first time together, these sources of variation on NMR in smokers screened for this clinical trial (N = 1,672).
RESULTS: Participants (mean age = 45.9) were 65.1% Caucasian, 34.9% African American, and 54.8% male. Mean NMR (SD) was higher in Caucasians versus African Americans [0.41 (0.20) vs. 0.33 (0.21); P < 0.001], and in females versus males [0.41 (0.22) vs. 0.37 (0.20); P < 0.001]. Among females, birth control pill use (N = 17) and hormone replacement therapy (N = 14) were associated with 19.5% (P = 0.09) and 29.3% (P = 0.06) higher mean NMR, respectively, albeit nonsignificantly. BMI was negatively associated with NMR (Rho = -0.14; P < 0.001), whereas alcohol use (Rho = 0.11; P < 0.001) and cigarette consumption (Rho = 0.12; P < 0.001) were positively associated with NMR. NMR was 16% lower in mentholated cigarette users (P < 0.001). When analyzed together in a linear regression model, these predictors (each ≤2%) accounted for <8% of total NMR variation.
CONCLUSIONS: Although these factors significantly affected NMR, they contributed little (together <8%; each ≤2%) to total NMR variation. IMPACT: Thus, when using NMR, for example, to prospectively guide smoking cessation therapy, these sources of variation are unlikely to cause NMR misclassification. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25012994      PMCID: PMC4154993          DOI: 10.1158/1055-9965.EPI-14-0427

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  54 in total

1.  Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Authors:  Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia
Journal:  J Natl Cancer Inst       Date:  2012-01-25       Impact factor: 13.506

2.  The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.

Authors:  Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

3.  Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation.

Authors:  Andy Z X Zhu; Matthew J Binnington; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Irina Stepanov; Clifford H Watson; Connie S Sosnoff; Neal L Benowitz; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2012-10-01       Impact factor: 4.944

4.  Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys.

Authors:  C S Ferguson; S Miksys; R M Palmour; R F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2012-08-30       Impact factor: 4.030

5.  Reproducibility of the nicotine metabolite ratio in cigarette smokers.

Authors:  Gideon St Helen; Maria Novalen; Daniel F Heitjan; Delia Dempsey; Peyton Jacob; Adel Aziziyeh; Victoria C Wing; Tony P George; Rachel F Tyndale; Neal L Benowitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-02       Impact factor: 4.254

6.  Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine.

Authors:  Mehmet Sofuoglu; Aryeh I Herman; Haleh Nadim; Peter Jatlow
Journal:  Neuropsychopharmacology       Date:  2012-02-15       Impact factor: 7.853

Review 7.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

8.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

9.  21st-century hazards of smoking and benefits of cessation in the United States.

Authors:  Prabhat Jha; Chinthanie Ramasundarahettige; Victoria Landsman; Brian Rostron; Michael Thun; Robert N Anderson; Tim McAfee; Richard Peto
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

10.  Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression.

Authors:  W James Gilmore; Georgy Hartmann; Micheline Piquette-Miller; Jason Marriott; Gordon M Kirby
Journal:  Toxicology       Date:  2003-03-03       Impact factor: 4.221

View more
  61 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.

Authors:  Ahmed El-Boraie; Taraneh Taghavi; Meghan J Chenoweth; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Nicole L Nollen; Neal L Benowitz; Rachel F Tyndale
Journal:  Addict Biol       Date:  2019-02-27       Impact factor: 4.280

3.  Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum.

Authors:  Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale
Journal:  Addiction       Date:  2018-07-23       Impact factor: 6.526

4.  The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.

Authors:  Meghan J Chenoweth; Robert A Schnoll; Maria Novalen; Larry W Hawk; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Nicotine Tob Res       Date:  2015-06-11       Impact factor: 4.244

5.  Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users.

Authors:  Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2015-05-14       Impact factor: 4.244

6.  Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers.

Authors:  Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan
Journal:  Nicotine Tob Res       Date:  2015-05-19       Impact factor: 4.244

7.  Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

8.  Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

Authors:  Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale
Journal:  Lancet Respir Med       Date:  2015-01-12       Impact factor: 30.700

9.  Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Authors:  Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll
Journal:  Addict Behav       Date:  2017-07-12       Impact factor: 3.913

10.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.